E-cadherin inactivation by Trop-2 drives metastases in TNBC

Correlation of Trop-2 expression with clinicopathological characteristics and outcome in TNBCПодробнее

TROP2: A Promising Breast Cancer Drug TargetПодробнее

Stabilization of E-cadherin adhesions and metastatic breast cancerПодробнее

Functional inactivation of E-cadherin drives EMT-less metastasisПодробнее

Can anthracyclines be omitted in TNBC?Подробнее

Potential new drugs with activity in metastatic TNBCПодробнее

Oncology appointments for Metastatic Triple Negative Breast Cancer #TNBC #Breast Cancer #RadiationПодробнее

Why Don't We Know More About Triple Negative Breast Cancer? #breastcancerПодробнее

Sacituzumab govitecan effective for HR+ metastatic breast cancer regardless of Trop-2 statusПодробнее

Enhancing triple negative breast cancer treatment with immunotherapy across all settingsПодробнее

ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously tre...Подробнее

Utility of TRPS-1 Immunohistochemistry in Diagnosis of Metastatic Breast Carcinoma in...Подробнее

Promising novel approaches to the treatment of TNBCПодробнее

2021 West Oncology | Breast Cancer | New Advances for Metastatic TNBCПодробнее

Future Directions for Treatment of TNBCПодробнее

Copy of Dr. Adams on Immunotherapy in Triple-Negative Breast CancerПодробнее

Optimal chemotherapy combinations in TNBC gBRCA subtypesПодробнее

IMpassion130: Design and Preliminary EfficacyПодробнее